BACKGROUND: Various megaprostheses are currently available for reconstruction of the proximal femur after tumor resection. This study evaluates the survival and complications of a modular megaprosthesis for reconstruction of the proximal femur. MATERIALS AND METHODS: We studied the medical files of 109 tumor patients (age range 16-86 years) who underwent proximal femoral reconstruction with the MRP(®) megaprosthesis from 2002 to 2011. There were 70 patients with metastases, 34 patients with bone sarcomas, and five patients with hematological malignancies; 82 were primary and 27 were revision reconstructions. Mean follow-up was 2.5 years; 31 patients had a minimum five-year follow-up. We evaluated the survival and function of the patients, and the survival and complications of the megaprostheses. RESULTS: Survival was significantly higher for the patients with bone sarcomas compared to those with metastases and hematological malignancies. Mean MSTS functional score was similar between patients with bone sarcomas and those with hematological malignancies and metastases, and between patients with primary and those with revision reconstructions. Overall survival of the MRP(®) megaprostheses was 74 % at 5 and 9 years. Fourteen (13.6 %) major complications occurred at a mean period of 1.4 years (range 3 months to 4.5 years); these included infection (5.8 %), dislocation (3.9 %), local recurrence (2.9 %), and acetabular fracture (1 %). CONCLUSION: MRP(®) megaprostheses are a valuable reconstruction option after tumor resection of the proximal femur.
BACKGROUND: Various megaprostheses are currently available for reconstruction of the proximal femur after tumor resection. This study evaluates the survival and complications of a modular megaprosthesis for reconstruction of the proximal femur. MATERIALS AND METHODS: We studied the medical files of 109 tumorpatients (age range 16-86 years) who underwent proximal femoral reconstruction with the MRP(®) megaprosthesis from 2002 to 2011. There were 70 patients with metastases, 34 patients with bone sarcomas, and five patients with hematological malignancies; 82 were primary and 27 were revision reconstructions. Mean follow-up was 2.5 years; 31 patients had a minimum five-year follow-up. We evaluated the survival and function of the patients, and the survival and complications of the megaprostheses. RESULTS: Survival was significantly higher for the patients with bone sarcomas compared to those with metastases and hematological malignancies. Mean MSTS functional score was similar between patients with bone sarcomas and those with hematological malignancies and metastases, and between patients with primary and those with revision reconstructions. Overall survival of the MRP(®) megaprostheses was 74 % at 5 and 9 years. Fourteen (13.6 %) major complications occurred at a mean period of 1.4 years (range 3 months to 4.5 years); these included infection (5.8 %), dislocation (3.9 %), local recurrence (2.9 %), and acetabular fracture (1 %). CONCLUSION:MRP(®) megaprostheses are a valuable reconstruction option after tumor resection of the proximal femur.
Authors: G Gosheger; A Hillmann; N Lindner; R Rödl; C Hoffmann; H Bürger; W Winkelmann Journal: Clin Orthop Relat Res Date: 2001-12 Impact factor: 4.176
Authors: Andreas F Mavrogenis; Panayiotis J Papagelopoulos; Luis Coll-Mesa; Elisa Pala; Giovanni Guerra; Pietro Ruggieri Journal: Orthopedics Date: 2011-12 Impact factor: 1.390
Authors: Eric R Henderson; John S Groundland; Elisa Pala; Jeremy A Dennis; Rebecca Wooten; David Cheong; Reinhard Windhager; Rainer I Kotz; Mario Mercuri; Philipp T Funovics; Francis J Hornicek; H Thomas Temple; Pietro Ruggieri; G Douglas Letson Journal: J Bone Joint Surg Am Date: 2011-03-02 Impact factor: 5.284
Authors: Panayiotis J Papagelopoulos; Andreas F Mavrogenis; Olga D Savvidou; Ioannis S Benetos; Evanthia C Galanis; Panayotis N Soucacos Journal: Injury Date: 2007-12-03 Impact factor: 2.586
Authors: Benjamin K Potter; Vincent E Chow; Sheila C Adams; G Douglas Letson; H Thomas Temple Journal: Surg Oncol Date: 2008-10-02 Impact factor: 3.279
Authors: Joseph L Finstein; Joseph J King; Edward J Fox; Christian M Ogilvie; Richard D Lackman Journal: Clin Orthop Relat Res Date: 2007-06 Impact factor: 4.176
Authors: Nicholas M Bernthal; Adam J Schwartz; Daniel A Oakes; J Michael Kabo; Jeffrey J Eckardt Journal: Clin Orthop Relat Res Date: 2010-11 Impact factor: 4.176
Authors: Maria Serena Oliva; Francesco Muratori; Raffaele Vitiello; Antonio Ziranu; Lorenzo Foschi; Giuseppe Rovere; Cesare Meschini; Domenico Andrea Campanacci; Giulio Maccauro Journal: BMC Musculoskelet Disord Date: 2022-09-06 Impact factor: 2.562
Authors: Christoph Theil; Jan Schwarze; Georg Gosheger; Burkhard Moellenbeck; Kristian Nikolaus Schneider; Niklas Deventer; Sebastian Klingebiel; George Grammatopoulos; Friedrich Boettner; Tom Schmidt-Braekling Journal: Cancers (Basel) Date: 2022-01-11 Impact factor: 6.639